Twin Peaks Wealth Advisors’s ADC Therapeutics ADCT Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8	Buy	+2	New	+$8	﹤0.01%	2367

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Twin Peaks Wealth Advisors's ADCT Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in ADC Therapeutics (ADCT) in Q1 2026: 2 shares worth $8. The stake represents ﹤0.01% of the portfolio and ranks #2367 among its holdings.

118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

Twin Peaks Wealth Advisors held 2 shares of ADC Therapeutics worth $8 as of Q1 2026.
ADC Therapeutics was a new Twin Peaks Wealth Advisors position in Q1 2026.
ADC Therapeutics made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #2367 holding.
118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.